Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735917 · ClinicalTrials.gov registry record · Phase 2
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00735917: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00735917 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00735917, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This phase II trial is studying how well saracatinib works in treating patients with previously treated metastatic pancreatic cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER pharmacological study
- RADIATION fludeoxyglucose F 18
- PROCEDURE positron emission tomography
- OTHER pharmacogenomic studies
- DRUG saracatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00735917
The ClinicalTrials.gov registry entry for NCT00735917 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which pharmacological study is the first listed.
NCT00735917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00735917 about?
NCT00735917 is a clinical study titled "Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer". This phase II trial is studying how well saracatinib works in treating patients with previously treated metastatic pancreatic cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00735917?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2008-10. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00735917?
The interventions under investigation include: pharmacological study (OTHER), fludeoxyglucose F 18 (RADIATION), positron emission tomography (PROCEDURE), pharmacogenomic studies (OTHER), saracatinib (DRUG).
Who is sponsoring clinical trial NCT00735917?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.